Rheumatoid arthritis and cardiovascular disease

The role of systemic inflammation and evolving strategies of prevention

Research output: Contribution to journalReview article

54 Citations (Scopus)

Abstract

Purpose of review: The incidence and mortality of cardiovascular disease are increased in the context of rheumatoid arthritis. The purpose of this review is to examine our evolving understanding of the pathogenesis of cardiovascular disease in rheumatoid arthritis and to underscore the importance of tailored prevention of cardiovascular disease in this select population. Recent findings: Recent reports have highlighted the shared pathobiology of cardiovascular disease and rheumatoid arthritis, both of which represent inflammatory disorders. Several reports have also provided much-needed insight into the deleterious impact that select therapies (including cyclo-oxygenase-2 - specific inhibitors) may have in terms of the risk of cardiovascular disease in rheumatoid arthritis. Although further study is warranted, preliminary investigations also suggest that aggressive anti-inflammatory therapy, including the adjunctive use of statins, may play important cardioprotective roles in rheumatoid arthritis. Summary: The pathogenesis of cardiovascular disease in rheumatoid arthritis is complex and involves several intermediate factors, including dyslipidemia, elevations in serum homocysteine, impaired insulin sensitivity, and endothelial dysfunction. Given the burden of cardiovascular disease in this population, it is important that health care providers caring for rheumatoid arthritis patients adopt a treatment course that is both comprehensive and individualized to address specific risk factors for cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)234-241
Number of pages8
JournalCurrent Opinion in Rheumatology
Volume17
Issue number3
DOIs
StatePublished - May 1 2005

Fingerprint

Rheumatoid Arthritis
Cardiovascular Diseases
Inflammation
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Homocysteine
Prostaglandin-Endoperoxide Synthases
Dyslipidemias
Health Personnel
Population
Insulin Resistance
Anti-Inflammatory Agents
Therapeutics
Mortality
Incidence
Serum

Keywords

  • 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
  • Cardiovascular disease
  • Congestive heart failure
  • Endothelial dysfunction
  • Glucocorticoid
  • Homocysteine
  • Myocardial infarction
  • Nonsteroidal anti-inflammatory drugs
  • Rheumatoid arthritis
  • Statin

ASJC Scopus subject areas

  • Rheumatology

Cite this

@article{a331ef5ce8b5447484a32009876eb22f,
title = "Rheumatoid arthritis and cardiovascular disease: The role of systemic inflammation and evolving strategies of prevention",
abstract = "Purpose of review: The incidence and mortality of cardiovascular disease are increased in the context of rheumatoid arthritis. The purpose of this review is to examine our evolving understanding of the pathogenesis of cardiovascular disease in rheumatoid arthritis and to underscore the importance of tailored prevention of cardiovascular disease in this select population. Recent findings: Recent reports have highlighted the shared pathobiology of cardiovascular disease and rheumatoid arthritis, both of which represent inflammatory disorders. Several reports have also provided much-needed insight into the deleterious impact that select therapies (including cyclo-oxygenase-2 - specific inhibitors) may have in terms of the risk of cardiovascular disease in rheumatoid arthritis. Although further study is warranted, preliminary investigations also suggest that aggressive anti-inflammatory therapy, including the adjunctive use of statins, may play important cardioprotective roles in rheumatoid arthritis. Summary: The pathogenesis of cardiovascular disease in rheumatoid arthritis is complex and involves several intermediate factors, including dyslipidemia, elevations in serum homocysteine, impaired insulin sensitivity, and endothelial dysfunction. Given the burden of cardiovascular disease in this population, it is important that health care providers caring for rheumatoid arthritis patients adopt a treatment course that is both comprehensive and individualized to address specific risk factors for cardiovascular disease.",
keywords = "3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, Cardiovascular disease, Congestive heart failure, Endothelial dysfunction, Glucocorticoid, Homocysteine, Myocardial infarction, Nonsteroidal anti-inflammatory drugs, Rheumatoid arthritis, Statin",
author = "Snow, {Marcus H} and Mikuls, {Ted R}",
year = "2005",
month = "5",
day = "1",
doi = "10.1097/01.bor.0000159924.97019.25",
language = "English (US)",
volume = "17",
pages = "234--241",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Rheumatoid arthritis and cardiovascular disease

T2 - The role of systemic inflammation and evolving strategies of prevention

AU - Snow, Marcus H

AU - Mikuls, Ted R

PY - 2005/5/1

Y1 - 2005/5/1

N2 - Purpose of review: The incidence and mortality of cardiovascular disease are increased in the context of rheumatoid arthritis. The purpose of this review is to examine our evolving understanding of the pathogenesis of cardiovascular disease in rheumatoid arthritis and to underscore the importance of tailored prevention of cardiovascular disease in this select population. Recent findings: Recent reports have highlighted the shared pathobiology of cardiovascular disease and rheumatoid arthritis, both of which represent inflammatory disorders. Several reports have also provided much-needed insight into the deleterious impact that select therapies (including cyclo-oxygenase-2 - specific inhibitors) may have in terms of the risk of cardiovascular disease in rheumatoid arthritis. Although further study is warranted, preliminary investigations also suggest that aggressive anti-inflammatory therapy, including the adjunctive use of statins, may play important cardioprotective roles in rheumatoid arthritis. Summary: The pathogenesis of cardiovascular disease in rheumatoid arthritis is complex and involves several intermediate factors, including dyslipidemia, elevations in serum homocysteine, impaired insulin sensitivity, and endothelial dysfunction. Given the burden of cardiovascular disease in this population, it is important that health care providers caring for rheumatoid arthritis patients adopt a treatment course that is both comprehensive and individualized to address specific risk factors for cardiovascular disease.

AB - Purpose of review: The incidence and mortality of cardiovascular disease are increased in the context of rheumatoid arthritis. The purpose of this review is to examine our evolving understanding of the pathogenesis of cardiovascular disease in rheumatoid arthritis and to underscore the importance of tailored prevention of cardiovascular disease in this select population. Recent findings: Recent reports have highlighted the shared pathobiology of cardiovascular disease and rheumatoid arthritis, both of which represent inflammatory disorders. Several reports have also provided much-needed insight into the deleterious impact that select therapies (including cyclo-oxygenase-2 - specific inhibitors) may have in terms of the risk of cardiovascular disease in rheumatoid arthritis. Although further study is warranted, preliminary investigations also suggest that aggressive anti-inflammatory therapy, including the adjunctive use of statins, may play important cardioprotective roles in rheumatoid arthritis. Summary: The pathogenesis of cardiovascular disease in rheumatoid arthritis is complex and involves several intermediate factors, including dyslipidemia, elevations in serum homocysteine, impaired insulin sensitivity, and endothelial dysfunction. Given the burden of cardiovascular disease in this population, it is important that health care providers caring for rheumatoid arthritis patients adopt a treatment course that is both comprehensive and individualized to address specific risk factors for cardiovascular disease.

KW - 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

KW - Cardiovascular disease

KW - Congestive heart failure

KW - Endothelial dysfunction

KW - Glucocorticoid

KW - Homocysteine

KW - Myocardial infarction

KW - Nonsteroidal anti-inflammatory drugs

KW - Rheumatoid arthritis

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=18144386863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18144386863&partnerID=8YFLogxK

U2 - 10.1097/01.bor.0000159924.97019.25

DO - 10.1097/01.bor.0000159924.97019.25

M3 - Review article

VL - 17

SP - 234

EP - 241

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 3

ER -